DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Hepatitis B Virus (HBV) Therapeutics - 5EU Drug Forecast and Market Analysis to 2024" report to their offering.
The chronic hepatitis B therapeutics market in the 5EU was valued at $532.1m in 2014. The anticipated arrival of novel branded therapies will be the strongest market driver in the 5EU during the forecast period. These therapies include Gilead's TAF, a novel NA, along with three adjunct therapies, Arrowhead's ARC-520, Gilead's GS-9620, and Gilead's GS-4774. GlobalData projects these four products will receive licensure in the 5EU in 2017, 2021, 2021, and 2023, respectively.
- Overview of HBV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU, including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting the 5EU HBV market.
Key Topics Covered:
1. Tables & Figures
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.2 Etiology and Pathophysiology
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
5 Competitive Assessment
5.2 Product Profiles - Major Brands
5.3 Other Therapeutics
6 Unmet Need and Opportunity
6.2 Improvements in Long-Term Clinical Outcomes
6.3 Enhanced Public Awareness and Screening Initiatives to Boost Diagnosis Rates
6.4 Increased Access to Treatment
6.5 Drugs That Effectively Target and Suppress HBV cccDNA
6.6 Safe and Efficacious Therapies for Difficult-to-Treat Patients
6.7 Overcome Unique Barriers Posed by China's Healthcare System
7 Pipeline Assessment
7.2 Clinical Trial Mapping
7.3 Promising Drugs in Clinical Development
7.4 Other Drugs in Development
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/h8gk3x/hepatitis_b_virus.